# Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects

> **NCT06280534** · PHASE1 · UNKNOWN · sponsor: **Xi'an Xintong Pharmaceutical Research Co.,Ltd.** · enrollment: 128 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** Test drug XT1061 capsules and placebo,Single dose group
- **DRUG:** Test drug XT1061 capsules and placebo，Multiple dosing group
- **DRUG:** Test drug XT1061 capsules and placebo，Food Impact Group

## Key facts

- **NCT ID:** NCT06280534
- **Lead sponsor:** Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-18
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-03-31
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06280534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06280534, "Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06280534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*